414 related articles for article (PubMed ID: 2031201)
1. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Rosso A
Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.
Hortobagyi GN; Bodey GP; Buzdar AU; Frye D; Legha SS; Malik R; Smith TL; Blumenschein GR; Yap HY; Rodriguez V
J Clin Oncol; 1987 Mar; 5(3):354-64. PubMed ID: 3819804
[TBL] [Abstract][Full Text] [Related]
5. Lonidamine in high-risk breast cancer patients.
Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
[TBL] [Abstract][Full Text] [Related]
6. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
Buccheri G; Ferrigno D
Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
Lopez M; Papaldo P; Di Lauro L; Vici P; Carpano S; Conti EM
Oncology; 1989; 46(1):1-5. PubMed ID: 2915887
[TBL] [Abstract][Full Text] [Related]
8. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
9. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Amadori D; Frassineti GL; De Matteis A; Mustacchi G; Santoro A; Cariello S; Ferrari M; Nascimben O; Nanni O; Lombardi A; Scarpi E; Zoli W
Breast Cancer Res Treat; 1998 Jun; 49(3):209-17. PubMed ID: 9776504
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
; Ambrosini G; Balli M; Garusi G; Demicheli R; Jirillo A; Bonciarelli G; Bruscagnin G; Fila G; Bumma C; Lacroix F; Buzzi F; Di Costanzo F; Padalino D; Brugia M; Calabresi F; Natali M; Cartei G; Chiesa G; Blasina B; Ciambellotti E; Moro G; D'Aquino S; Altavilla G; Adamo V; De Maria D; Falchi AM; Bertoncelli P; Farris A; Fiorentino M; Fornasiero A; Fosser V; Daniele O; Foggi CM; Speranza GB; Sartori S; Camilluzzi E; Gallo L; Poggio R; Secondo V; Gambi A; Grignani F; Capodicasa E; Lopez M; Papaldo P; Di Lauro L; Vici P; Marenco G; Folco U; Bonanni F; Marsilio P; Palazzotto G; Di Carlo A; Cusimano MP; Pastorino G; Puccetti C; Giusto M; Rausa L; Gebbia N; Palmeri S; D'Alessandro N; Saccani F; Becchi G; Schieppati G; Spinelli I; Tagliagambe A; Tonato M; Minotti V; Ardia A; Viaro D; De Micheli P; Zingali G; Sacchetti G; Intini C
J Clin Oncol; 1988 Jun; 6(6):976-82. PubMed ID: 2897433
[TBL] [Abstract][Full Text] [Related]
11. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Jassem J; Pieńkowski T; Płuzańska A; Jelic S; Gorbunova V; Mrsic-Krmpotic Z; Berzins J; Nagykalnai T; Wigler N; Renard J; Munier S; Weil C;
J Clin Oncol; 2001 Mar; 19(6):1707-15. PubMed ID: 11251000
[TBL] [Abstract][Full Text] [Related]
13. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
[TBL] [Abstract][Full Text] [Related]
14. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
15. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
[TBL] [Abstract][Full Text] [Related]
17. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
19. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
[TBL] [Abstract][Full Text] [Related]
20. [Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].
Boér K; Láng I; Juhos E; Pintér T; Szántó J
Magy Onkol; 2003; 47(2):141-8. PubMed ID: 12975660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
